Ligand-Drug Conjugates With Exatecan Analogues for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-cancer therapies, including chemotherapy, surgery, radiotherapy, and targeted therapy, face challenges due to the limited difference between tumor cells and normal cells, leading to toxic side effects and inadequate efficacy, while antibody drug conjugates (ADCs) struggle to effectively target solid tumors.
Innovation Solution
Development of ligand-drug conjugates of exatecan analogues, specifically compounds with novel structures, linked via a covalent linker to antibodies like patritumab, cofetuzumab, or trastuzumab, to selectively target and kill cancer cells, enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy drugs are used, then anti-tumor efficacy is achieved, but toxic side effects increase due to lack of specificity between tumor and normal cells
Solution Approach 1:
The therapy is segmented into two distinct functional components: a monoclonal antibody component that provides tumor-specific targeting and a cytotoxin component that provides potent cell killing. This segmentation allows each component to optimize its function while the combination resolves the contradiction between efficacy and toxicity by ensuring the cytotoxin is delivered only to tumor cells via the antibody's specific binding to tumor surface antigens
Solution Approach 2:
A monoclonal antibody serves as an intermediary carrier that selectively delivers the cytotoxin to tumor cells. The antibody binds with high specificity to tumor cell surface antigens, acting as a mediator that transports the toxic payload only to the intended target, thereby achieving effective tumor killing while minimizing harm to normal cells
2Object-affected harmful factors
If antibody drugs are used alone, then specificity for tumor cells is improved, but anti-tumor efficacy becomes insufficient
Solution Approach 1:
The invention merges the monoclonal antibody with a biologically active cytotoxin through a chemically stable linker to form an antibody drug conjugate. This combination allows the antibody's specificity to tumor cells to be combined with the cytotoxin's high efficacy, achieving both selective targeting and potent anti-tumor activity simultaneously
Solution Approach 2:
The antibody drug conjugate functions as a composite therapeutic agent combining biological (antibody) and chemical (cytotoxin) components. This composite structure enables the therapy to exhibit both the specificity of the antibody and the high efficacy of the cytotoxin, resolving the limitation of using antibodies alone
3Reliability
If antibody drug conjugates are developed, then specificity and efficacy are improved, but development complexity increases
Solution Approach 1:
The invention optimizes key parameters of the antibody drug conjugate including the choice of cytotoxin (e.g., camptothecin derivatives), the type of chemically stable linker used, and the ratio of antibody to cytotoxin in the conjugate. By carefully controlling these parameters, the complex conjugate structure is designed to achieve optimal efficacy while maintaining stability and reducing unwanted complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ligand-drug conjugates demonstrate potent cellular killing and bystander killing effects, effectively reducing tumor growth and metastasis, as shown in various cancer cell lines and xenograft models.
Implementation Method 1
linked via a covalent linker to antibodies like patritumab, cofetuzumab, or trastuzumab
Data Source
AI summary
Provided herein are compounds having formulas (I) or (VII):or pharmaceutically acceptable salts, tautomers, isotopologues, stereoisomers, or prodrugs thereof, wherein the substituents are as described herein;ligand-drug conjugates and pharmaceutically acceptable salts or solvates thereof, wherein the ligand-drug conjugate comprises a residue of the compound provided here; andmethods of treating cancer thereof.